GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (XSGO:LLYCL) » Definitions » Total Equity

Eli Lilly and Co (XSGO:LLYCL) Total Equity : CLP12,501,255 Mil (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Eli Lilly and Co Total Equity?

Eli Lilly and Co's total equity for the quarter that ended in Sep. 2024 was CLP12,501,255 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Eli Lilly and Co Total Equity Historical Data

The historical data trend for Eli Lilly and Co's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Total Equity Chart

Eli Lilly and Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,009,803.82 4,246,337.74 7,930,345.19 9,342,379.83 9,483,466.76

Eli Lilly and Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10,254,002.25 9,483,466.76 11,258,785.15 11,903,109.54 12,501,254.87

Eli Lilly and Co Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Eli Lilly and Co's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=55874298.694-46390831.93
=9,483,467

Eli Lilly and Co's Total Equity for the quarter that ended in Sep. 2024 is calculated as

Total Equity=Total Assets(Q: Sep. 2024 )-Total Liabilities(Q: Sep. 2024 )
=66001042.302-53499787.437
=12,501,255

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co Total Equity Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Eli Lilly and Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (XSGO:LLYCL) » Definitions » Total Equity
Comparable Companies
JNJ ABBV MRK AMGN PFE BMY GILD BIIB OGN AMRN OCSE:NOVO B XSWX:ROG XSWX:NOVN LSE:AZN XPAR:SAN LSE:GSK TSE:4519 TSE:4568 SHSE:600276 TSE:4578
Traded in Other Exchanges
LLY:USA LLY:Mexico 1LLY:Italy LLY0:Germany LLY:Germany LLY:Germany LLY:Germany LLY:Germany LLY:Switzerland LLY:Canada LILY34:Brazil LLY:Bulgaria LLYC:Austria LLY:Argentina
Address
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Website
https://www.lilly.com
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly and Co Headlines

No Headlines